ICON Announces Appointment of Dr. Hugh Brady to Board of Directors
30 Avril 2014 - 12:15PM
Business Wire
ICON plc, (NASDAQ: ICLR), a global provider of outsourced
development services to the pharmaceutical, biotechnology and
medical device industries, today announced the appointment of Dr.
Hugh Brady as a non-executive director.
Dr. Brady is President Emeritus of University College Dublin
(UCD), one of Europe’s leading research-intensive universities,
where he served as President from 2004 until the end of 2013.
During his tenure Dr. Brady oversaw a significant expansion of
UCD’s science, engineering and biomedical research capacity,
including the development of the Conway Institute for Biomedical
Research, UCD Clinical Research Centre and the Dublin Academic
Medical Centre. In addition, he led a major growth in UCD’s
international footprint, including the establishment of the
Beijing-Dublin International College and the UCD Shenzhen Health
Sciences Institute in China.
A nephrologist by training, Dr. Brady was Professor of Medicine
and Therapeutics at UCD before being appointed the university’s
President. He returned to Ireland having built a successful career
as a physician and biomedical research scientist in the US, where
he spent nine years at Harvard University, including a period as
Associate Professor of Medicine. In parallel with his academic
career at Harvard, he served as Director of the Renal Division of
the Brockton/West Roxbury VA Medical Center and Consultant
Physician at the Brigham and Women’s Hospital, Boston. He has an
international reputation in the pathogenesis of diabetic kidney
disease and renal inflammation.
Dr. Brady has held many national and international leadership
roles, including Chairman of the Irish Health Research Board and
Chairman of the Universitas 21 Network of global research
universities. He is also a non-executive director of Kerry Group
plc.
“I am very pleased that Dr Brady has joined the board” commented
Mr. Thomas Lynch, Chairman. “His inspirational leadership of UCD,
Irelands’ largest university, during the past ten years, extensive
international experience, especially in Asia coupled with a
distinguished career as an academic clinician in Ireland and the
United States will bring invaluable experience and expertise to
ICON.”
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON plc is a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries.
The company specialises in the strategic development, management
and analysis of programs that support clinical development - from
compound selection to Phase I-IV clinical studies. With
headquarters in Dublin, Ireland, ICON currently, operates from 76
locations in 37 countries and has approximately 10,300 employees.
Further information is available at www.iconplc.com.
Source: ICON plc
All at ICON.
ICON/ICLR-F
ICON plcInvestor Relations1-888-381-7923orBrendan BrennanChief
Financial Officer+ 353 –1-291-2000orSimon HolmesEVP Investor
Relations and Corporate Development+ 353 –1-291-2000
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Juil 2024 à Août 2024
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Août 2023 à Août 2024